Skip to content

Current Debt at other companies

Amgen logo
AmgenAMGN
$5.44B+61.4%
Incyte logo
IncyteINCY
$4.41M-1.5%
Eli Lilly logo
Eli LillyLLY
$4B-0.4%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
Moderna logo
ModernaMRNA

Other financials

Income statement

See full
Operating income-$71.9M-8.9%
Net income-$70.9M-6.9%
EPS (diluted)-$0.77+2.5%

Balance sheet

See full
Cash & equivalents$124.7M-28.3%
Total debt$79.2M+0.5%
Total equity$210.5M-56.4%
Total assets$333.6M-44.7%

Cash flow

See full
Operating cash flow-$66.0M-30.1%
CapEx$135.0K-92.5%
Free cash flow-$66.1M-25.9%

Valuation

See full
Market cap$930.59M+30.2%
Enterprise value$885.15M+30.0%

Returns & leverage

See full
Return on equity-90.9%+362pp
Debt / equity0.4×+0.2×
Current ratio5.6×-5.8×

Where this comes from

Reported directly by Replimune Group in its filing.

Tagged under the XBRL concept us-gaap:FinanceLeaseLiabilityCurrent.

The official record: Replimune Group’s 10-Q, filed February 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Replimune Group's current debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Replimune Group's current debt?
Replimune Group (REPL) reported current debt of $2.86M in Q4 2025.
How has Replimune Group's current debt changed year-over-year?
Replimune Group's current debt increased by 3.0% year-over-year, from $2.78M to $2.86M.
What is the long-term trend for Replimune Group's current debt?
Over 4 years (2021 to 2025), Replimune Group's current debt has grown at a 3.0% compound annual growth rate (CAGR), from $2.49M to $2.8M.
What does current debt mean?
The portion of long-term debt maturing within the next 12 months, requiring refinancing or repayment from operating cash flows.